Loading...
By Kelly Young
Edited by André Sofair, MD, MPH, and William E. Chavey, MD, MS
The pharmaceutical division of Johnson & Johnson says it will establish an independent bioethics panel to evaluate patients' requests for drugs that have not been FDA approved and are often in limited supply.
The Compassionate-Use Advisory Committee (CompAC), chaired by bioethicist Arthur Caplan, will comprise 10 physicians, ethicists, and patient advocates. Janssen Pharmaceutical Companies of J&J said it will begin with a single investigational drug. If the process works, it could become a model for other investigational products, as well as for other pharmaceutical companies.
J&J told the Times that it receives at least 100 requests a year for compassionate use of investigational drugs.
The company already offers an expanded access program for investigational drugs when clinical trials show the benefits outweigh the risks and the drug is in the process of being approved. In these cases, patients who have the disease for which the drug was studied and are out of treatment options can qualify for expanded access. Going forward, if patients don't qualify for expanded access or a clinical trial, CompAC will consider the request.
Comment
LINK(S):
Johnson & Johnson news release (Free)
New York Times story (Free)
FDA information on compassionate use (Free)
Background: Physician's First Watch coverage quoting Arthur Caplan on proposed kidney transplant rules (Free)